Anti-Monkeypox virus/MPXV M1R Antibody (SAA2429) from ProteoGenix; catalogue ARO-A22877; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Your ultimate solution for combating the Monkeypox virus.
This powerful antibody is specifically designed to target the Monkeypox virus, a zoonotic disease that is caused by the Monkeypox virus (MPXV). With the recent outbreaks of Monkeypox in various parts of the world, the need for effective treatments has become more urgent than ever before.
The Anti-Monkeypox virus/MPXV M1R Antibody (SAA2429) is a highly specific and potent antibody that binds to the M1R protein on the surface of the Monkeypox virus. This binding blocks the virus from entering and infecting host cells, effectively neutralizing its harmful effects.
This antibody has a wide range of applications, making it an essential tool for researchers and clinicians alike. It can be used for diagnostic purposes, as well as for the development of vaccines and therapeutics against Monkeypox virus infections.
In experimental use cases, the Anti-Monkeypox virus/MPXV M1R Antibody (SAA2429) has shown promising results in reducing viral load and preventing the spread of the virus. It has also been proven to be highly effective in protecting against Monkeypox virus infection in animal models.
With its high specificity and potency, this antibody is a valuable asset for any biotech company or research institution working towards finding a cure for Monkeypox virus. Its use can greatly accelerate the development of effective treatments and ultimately save lives.
In summary, the Anti-Monkeypox virus/MPXV M1R Antibody (SAA2429) is a cutting-edge product that offers a targeted and potent solution for combating the Monkeypox virus. Its wide range of applications and proven effectiveness make it a valuable addition to any research or clinical setting. Don’t wait any longer – get your hands on this powerful antibody today and join the fight against Monkeypox virus.
ProteoGenix catalogue number ARO-A22877. For research use only.
Target: Entry-fusion complex associated protein OPG095, EFC-associated protein OPG095, Protein L1, OPG099; Clonality: Monoclonal Antibody; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Entry-fusion complex associated protein OPG095, EFC-associated protein OPG095, Protein L1, OPG099 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
